Tianjin Zhong Xin Pharmaceutical Group Corporation has recorded earnings of RMB661.7 million ($135.8 million) or 0.86 RMB cents per share for the FY2020 ended December, 6% higher than earnings of RMB625.6 million a year ago.

FY2020 revenue fell 6% y-o-y to RMB6.60 billion largely due to lower revenue brought in by the group’s Chinese medicine segment.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.

Bonus:

  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply

Subscribe

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook